Developmental Determinants of Cardiovascular Disease

这是范德比尔特大学儿科心脏病学部首次续签T32申请 医学院。通过推进一项将正式培训整合到发展研究中的计划 心血管疾病的决定因素随着儿科心脏病学的临床培训，我们将提供独特的 将促进儿科心脏病学术专家发展的培训环境。这项培训计划将 不仅关注先天性心脏病的分子和遗传病因，而且还将强调 出生前和出生后发育对确定出生后心血管病理表现的影响 除了儿科心脏病学的实习生外，临床或博士后研究员拥有 表示有兴趣研究心血管疾病发展机制的人将有资格获得 支持。我们要求继续支持3名学员/年，为期两年，总共6名学员/年 为期五年。该计划将为学员提供一个独特的机会来学习重述 心血管疾病个体发生中的正常发育过程，表现在童年后期或 成人期。该计划将由两个轨道组成，为追求(1)基本的准备而优化 科学研究或(2)临床或转化性研究。专注、有指导的实验室体验 有针对性的教学互动将被量身定做，以满足那些追求更基础科学职业的人的需求。 对于寻求临床或转化医学职业生涯的实习生来说，范德比尔特临床理学硕士 调查(MSCI)计划将是培训计划不可或缺的一部分。候选人将从以下方面确定 申请儿科心脏病研究金的申请者人数(2017年3个职位的112名申请者) 以及来自范德比尔特大学的有才华的临床和博士后研究员。在第一次临床试验中 儿科心脏病学奖学金年(PGY-4)候选人将与导师配对，他们一起 将决定一个研究项目。在四年奖学金的第二年和第三年，受训者将 开展有指导的研究项目。在第四年，学员将完成临床培训与 选择子专业的高级培训，以及继续研究和提交K08或 K23应用程序。这笔赠款将为第二和第三年的受保护研究培训提供支持。 儿科系致力于在第一年和第四年为研究员提供全面支持 以及在第二年和第三年由这笔赠款提供的补充支持。利用其独特的优势 范德比尔特大学心脏发育和再生、心肌生物学、肺脏 生物学和肺动脉高压，心血管遗传学和药物基因组学，血管生物学和 动脉粥样硬化，以及基于心血管结果的研究和生物信息学，该计划将有助于 培养专注于儿科心血管疾病的下一代内科科学家。

This is the first renewal of the T32 application from Division of Pediatric Cardiology, Vanderbilt University School of Medicine. By advancing a program that integrates formal training in research on developmental determinants of cardiovascular disease with clinical training in pediatric cardiology, we will provide a unique training environment that will foster development of academic pediatric cardiologists. This training program will not only focus on the molecular and genetic etiologies of congenital heart disease, but will also emphasize the impact of pre- and postnatal development in defining the manifestations of cardiovascular pathology after birth. In addition to trainees in the Pediatric Cardiology, clinical or Ph.D. post-doctoral fellows who have an expressed interest in investigating development mechanisms of cardiovascular disease will be eligible for support. We are requesting continued support for 3 trainees / year for two years for a total of 6 trainees / year for a five year period. This program will provide a unique opportunity for trainees to study the recapitulation of normal developmental processes in the ontogeny of cardiovascular pathology presenting later in childhood or adulthood. The program will be composed of two tracks optimized either for pursuit of preparation for (1) basic science investigation or (2) clinical or translational research. A focused, mentored, laboratory experience with targeted didactic interactions will be tailored to meet the needs of those pursing a more basic science career. For trainees pursuing a career in clinical or translational medicine, the Vanderbilt Master of Science in Clinical Investigation (MSCI) program will be an integral part of the training program. Candidates will be identified from the pool of applicants applying for a pediatric cardiology fellowship (112 applicants for 3 positions in 2017) as well as from talented clinical and post-doctoral fellows throughout Vanderbilt University. During a first clinical year of pediatric cardiology fellowship (PGY-4) the candidates will be matched with mentors and together, they will decide upon a research project. During the second and third years of a four year fellowship, trainees will carry out a mentored research project. During the fourth year, the trainee will complete clinical training with the option of advanced training in a sub-subspecialty as well as continued research and submission of a K08 or K23 application. This grant will provide support for the second and third years of protected research training. The Department of Pediatrics is committed to complete support of fellows during the first and fourth years as well as supplementing support provided by this grant in years two and three. Using the unique strengths of Vanderbilt University in the areas of cardiac development and regeneration, myocardial biology, pulmonary biology and pulmonary hypertension, cardiovascular genetics and pharmacogenomics, vascular biology and atherosclerosis, as well as cardiovascular outcomes based research and bioinformatics, the program will help train the next generation of physician scientists focused on pediatric cardiovascular disease.